Skip to main content
main-content

29.04.2017 | Family Planning (A Burke, Section Editor) | Ausgabe 2/2017

Current Obstetrics and Gynecology Reports 2/2017

Unscheduled Bleeding on Hormonal Contraceptives: Pathophysiology, Evaluation, and Management Options

Zeitschrift:
Current Obstetrics and Gynecology Reports > Ausgabe 2/2017
Autoren:
Shandhini Raidoo, Bliss Kaneshiro
Wichtige Hinweise
This article is part of the topical collection on Family Planning

Abstract

Purpose of Review

Unscheduled bleeding is a common side effect of hormonal contraception and is a common reason for method discontinuation. This review summarizes the pathophysiology, evaluation, and current evidence-based management recommendations for the unscheduled bleeding that can occur with hormonal contraception use.

Recent Findings

Prior to initiation of a hormonal contraceptive method, detailed structured counseling about the likelihood of unscheduled bleeding and its likely improvement with continued use is an important component of method continuation and patient satisfaction. For unscheduled bleeding that is persistent and bothersome, non-steroidal anti-inflammatory drugs (NSAIDs) and estrogen alone or estrogen and progestin in combined oral contraceptive (COC) are commonly used for management. The antibiotic doxycycline is somewhat effective at reducing unscheduled bleeding in users of combined hormonal contraceptive methods and progestin implants. Small randomized controlled trials of mifepristone, an antiprogestin, and tranexamic acid, an antifibrinolytic, demonstrated a decrease in unscheduled bleeding in users of depot medroxyprogesterone acetate (DMPA), progestin implants, and levonorgestrel intrauterine devices (IUDs). Tamoxifen, a selective estrogen receptor modulator (SERM), in progestin implant users reduces unscheduled bleeding. Ulipristal acetate, a selective progesterone receptor modulator (SPRM), is not effective at reducing unscheduled bleeding in levonorgestrel IUD users and may result in an increase in bleeding.

Summary

Expectant management is a mainstay of treatment of unscheduled bleeding that occurs as a result of hormonal contraceptive use. NSAIDs and COCs are commonly used for treatment. Small randomized controlled trials of other methods have demonstrated some effectiveness, although evidence is limited.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2017

Current Obstetrics and Gynecology Reports 2/2017 Zur Ausgabe

Family Planning (A Burke, Section Editor)

Misoprostol in Abortion Care: Review and Update

Emerging and Pipeline Technologies in Ob/Gyn (M Levie, Section Editor)

A High-Strength, Absorbable, Antibacterial Knotless Tissue Control Device for Fascial Closure

Reproductive Endocrinology and Infertility (REI) (R Anchan, Section Editor)

Genetic Screening and Early Recurrent Pregnancy Loss

Care for the Transgender Patient (C Unger, Section Editor)

Reproductive and Obstetrical Care for Transgender Patients

Care for the Transgender Patient (C Unger, Section Editor)

Hysterectomy for the Transgender Man

  1. Sie können e.Med Gynäkologie & Urologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Gynäkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise